查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1887164

GLP-1受體激動劑市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察與預測（2024-2032）

GLP-1 Receptor Agonist Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 請詢問到貨日

價格

GLP-1受體激動劑市場驅動因子

全球GLP-1受體激動劑市場正經歷顯著成長，這主要得益於糖尿病患者數量的增加、肥胖症盛行率的上升以及新一代GLP-1療法的廣泛應用。根據財富商業洞察（Fortune Business Insights）報告顯示，該市場預計在2024年達到520.8億美元，2025年增長至628.3億美元，並在2032年達到1866.4億美元，預測期內複合年增長率（CAGR）為16.8%。這一顯著增長反映了全球治療策略向晚期代謝疾病的轉變，以及GLP-1藥物因其血糖控制和體重減輕的雙重益處而日益受到認可。

市場洞察與驅動因素

GLP-1受體激動劑模擬人類胰高血糖素樣勝肽-1激素，可改善血糖控制、刺激胰島素分泌並支持長期體重管理。其廣泛應用主要受全球第二型糖尿病和肥胖症盛行率不斷上升的推動。根據國際衛生組織統計，第2型糖尿病影響全球超過10%的成年人口，而肥胖症的盛行率仍以驚人的速度持續成長。 GLP-1藥物可同時針對這兩種疾病，從而推動了主要醫療保健市場需求的快速成長。

此外，諾和諾德、禮來、阿斯特捷利康和賽諾菲等主要製藥公司正在不斷開發GLP-1製劑，包括每週一次注射劑、高劑量製劑、口服GLP-1製劑和聯合療法。給藥系統的創新以及對個人化治療日益增長的關注，也進一步推動了市場的擴張。

依地區劃分的市場亮點

2024年，北美在全球GLP-1受體激動劑市場佔主導地位，市佔率高達55.51%。該地區市場規模在2024年達到289.1億美元，主要得益於肥胖和糖尿病的高發生率、先進的治療基礎設施以及強勁的藥物研發投入。美國仍然是最大的貢獻者，這主要得益於Ozempic、Wegovy、Munjaro和Libelsus等GLP-1藥物的大規模生產擴張。

歐洲是第二大市場，這得益於主要製藥廠商的存在、日益活躍的臨床研究以及GLP-1療法在糖尿病和肥胖症治療中的應用不斷增長。同時，亞太地區正經歷快速增長，這主要歸功於生活方式相關疾病的增加、醫療保健覆蓋範圍的擴大以及人們對現代代謝療法的認識不斷提高。中國和日本等國家正越來越多地將GLP-1藥物引入臨床實踐。

市場趨勢與限制因素

影響市場發展的關鍵趨勢之一是將人工智慧和數位健康工具結合，以指導治療方案的選擇並優化患者療效。基於人工智慧的平台正越來越多地被用於預測特定患者的最佳GLP-1療法。

然而，市場成長仍受到限制。主要因素是GLP-1受體激動劑的高成本。在美國，平均每月治療費用約為1000美元，這使得許多患者難以負擔長期治療。此外，仿製藥供應受限以及全球需求激增導致的供應短缺也構成了額外的障礙。儘管面臨這些挑戰，但隨著主要公司擴大生產能力，預計未來幾年供應短缺的情況將有所緩解。

依細分市場分析

依藥物類型劃分，索瑪魯肽在2024年佔最大的市場佔有率，憑藉其高效性、每週一次的注射方案以及注射劑（Ozempic、Wegovy）和口服劑（Libelsus）兩種劑型，保持了其領先地位。艾塞那肽和利拉魯肽仍被廣泛使用，而替澤帕肽等新型藥物則呈現快速成長趨勢。

依年齡組別劃分，成人在2024年佔了大部分使用量，這反映了全球成人發病型第二型糖尿病和肥胖症的高發生率。由於用於治療青少年肥胖症的新藥獲批，GLP-1類藥物在兒童中的使用量正在上升。

依給藥途徑劃分，注射劑在2024年佔主導地位，但由於患者更傾向於非注射療法，口服製劑的需求正在迅速增長。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 主要適應症的流行情況（依主要國家/地區劃分，2024 年）
  • 主要公司的產品線分析
  • 主要公司新產品發布狀況
  • 主要產業趨勢（併購、合作等）
  • 新冠疫情對市場的影響

第五章：全球GLP-1受體激動劑市場分析、洞察與預測（2019-2032）

  • 市場分析、洞察與預測 - 依藥物分類
    • 索瑪魯肽
    • 艾塞那肽
    • 利西拉肽
    • 利拉魯肽
    • 度拉魯肽
    • 其他
  • 市場分析、洞察與預測 - 依給藥途徑
    • 口服
    • 注射
  • 市場分析、洞察與預測 - 依年齡組
    • 兒童
    • 成人
  • 市場分析、洞察與預測 - 依適應症
    • 糖尿病
    • 肥胖症
    • 其他
  • 市場分析、洞察與預測 - 依銷售額管道
    • 醫院藥房
    • 零售藥房
    • 線上藥房
  • 市場分析、洞察與預測 - 依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美 GLP-1 受體激動劑市場分析、洞察與預測 (2019-2032)

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲 GLP-1 受體激動劑市場分析、洞察與預測 (2019-2032)

  • 依國家/地區
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第八章：亞太地區 GLP-1 受體激動劑市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲 GLP-1 受體激動劑市場分析、洞察與預測（2019-2032）

  • 依國家/地區
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第十章：中東和非洲 GLP-1 受體激動劑市場分析、洞察與預測 (2019-2032)

  • 依國家劃分
    • 海灣合作委員會 (GCC)
    • 南非
    • 其他中東和非洲國家

第十一章：競爭分析

  • 全球市佔率分析 (2024)
  • 公司簡介
    • 禮來公司
    • 賽諾菲
    • 諾和諾德
    • 阿斯特捷利康
    • 輝瑞公司
    • 格蘭馬克製藥有限公司
    • 梯瓦製藥工業股份有限公司
Product Code: FBI112827

Growth Factors of GLP-1 receptor agonist Market

The global GLP-1 receptor agonist market is witnessing exceptional expansion driven by rising cases of diabetes, increasing obesity prevalence, and strong uptake of next-generation GLP-1 therapies. According to the Fortune Business Insights report, the market was valued at USD 52.08 billion in 2024, is projected to rise to USD 62.83 billion in 2025, and is expected to reach USD 186.64 billion by 2032, registering a CAGR of 16.8% over the forecast period. This significant acceleration reflects the global shift toward advanced metabolic disorder treatments and the growing acceptance of GLP-1 drugs for their dual benefits-blood glucose control and weight reduction.

Market Insights and Drivers

GLP-1 receptor agonists mimic the human glucagon-like peptide-1 hormone, improving glycemic control, stimulating insulin secretion, and supporting long-term weight management. Their widespread adoption stems from increasing global prevalence of type 2 diabetes and obesity. As per international health bodies, type 2 diabetes affects over 10% of the global adult population, and obesity continues to grow at alarming rates. Because GLP-1 drugs target both conditions simultaneously, their demand has surged sharply across major healthcare markets.

In addition, major pharmaceutical players such as Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca, and Sanofi continue to advance GLP-1 formulations, including once-weekly injectables, high-dose variations, oral GLP-1 options, and combination therapies. Innovations in delivery systems and the growing emphasis on personalized therapy are further supporting market expansion.

Regional Market Highlights

North America dominated the global GLP-1 receptor agonist market in 2024, accounting for 55.51% of total market share. The region's market value stood at USD 28.91 billion in 2024, driven by high obesity and diabetes rates, advanced treatment infrastructure, and strong pharmaceutical R&D investments. The United States remains the largest contributor, strengthened by large-scale manufacturing expansions for GLP-1 drugs such as Ozempic, Wegovy, Mounjaro, and Rybelsus.

Europe represents the second-largest market, supported by the presence of leading pharmaceutical manufacturers, rising clinical research activities, and increasing adoption of GLP-1 therapies for both diabetes and obesity. Meanwhile, Asia Pacific is experiencing rapid growth due to rising lifestyle-related diseases, expanding healthcare access, and growing awareness of modern metabolic therapies. Countries such as China and Japan are increasingly integrating GLP-1 drugs into clinical practice.

Market Trends and Restraints

A major trend shaping the market is the integration of AI and digital health tools that guide treatment selection and optimize patient outcomes. AI-based platforms are increasingly being used to predict which GLP-1 therapy will deliver the best efficacy for specific patient profiles.

However, market growth faces restraints, primarily the high cost of GLP-1 receptor agonists. Monthly treatment costs in the U.S. average around USD 1,000, making long-term therapy challenging for many patients. The limited availability of generics and supply shortages-due to overwhelming global demand-pose additional barriers. Despite these challenges, manufacturing expansions by leading companies are expected to reduce shortages in the coming years.

Segmentation Insights

By drug type, semaglutide held the largest share in 2024 and continues to dominate due to its strong efficacy, once-weekly injection schedule, and availability in both injectable (Ozempic, Wegovy) and oral (Rybelsus) forms. Exenatide and liraglutide also remain widely used, while newer agents such as tirzepatide are seeing rapid growth.

By age group, adults accounted for the majority of usage in 2024, reflecting the high global incidence of adult-onset type 2 diabetes and obesity. Pediatric use of GLP-1 drugs is increasing due to new approvals for adolescent obesity treatment.

By route of administration, parenteral GLP-1 agonists dominated in 2024, though oral formulations are growing quickly due to patient preference for non-injectable therapies.

Conclusion

The GLP-1 receptor agonist market is set for strong long-term expansion, rising from USD 52.08 billion in 2024 to USD 186.64 billion by 2032. As obesity and diabetes rates surge globally, and as GLP-1 therapies gain broader approval for multiple indications, the demand for advanced metabolic treatments will continue to accelerate. The presence of established players and active product pipelines ensures that the market remains highly competitive and innovation-driven.

Segmentation By Drug

  • Semaglutide
  • Exenatide
  • Lixisenatide
  • Liraglutide
  • Dulaglutide
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Age Group

  • Pediatric
  • Adults

By Indication

  • Diabetes
  • Obesity
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America (By Drug, By Route of Administration, By Age Group, By Indication, By Distribution Channel, and By Country)
    • U.S.
    • Canada
  • Europe (By Drug, By Route of Administration, By Age Group, By Indication, By Distribution Channel, and By Country/ Sub-region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug, By Route of Administration, By Age Group, By Indication, By Distribution Channel, and By Country/ Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug, By Route of Administration, By Age Group, By Indication, By Distribution Channel, and By Country/ Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug, By Route of Administration, By Age Group, By Indication, By Distribution Channel, and By Country/ Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Indications, By Key Countries/Regions, 2024
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. New Product Launches, by Key Players
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.5. Impact of COVID-19 on the Market

5. Global GLP-1 Receptor Agonists Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Drug
    • 5.1.1. Semaglutide
    • 5.1.2. Exenatide
    • 5.1.3. Lixisenatide
    • 5.1.4. Liraglutide
    • 5.1.5. Dulaglutide
    • 5.1.6. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatric
    • 5.3.2. Adults
  • 5.4. Market Analysis, Insights and Forecast - By Indication
    • 5.4.1. Diabetes
    • 5.4.2. Obesity
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Retail Pharmacies
    • 5.5.3. Online Pharmacies
  • 5.6. Market Analysis, Insights and Forecast - Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America GLP-1 Receptor Agonists Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Drug
    • 6.1.1. Semaglutide
    • 6.1.2. Exenatide
    • 6.1.3. Lixisenatide
    • 6.1.4. Liraglutide
    • 6.1.5. Dulaglutide
    • 6.1.6. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatric
    • 6.3.2. Adults
  • 6.4. Market Analysis, Insights and Forecast - By Indication
    • 6.4.1. Diabetes
    • 6.4.2. Obesity
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Retail Pharmacies
    • 6.5.3. Online Pharmacies
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe GLP-1 Receptor Agonists Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Drug
    • 7.1.1. Semaglutide
    • 7.1.2. Exenatide
    • 7.1.3. Lixisenatide
    • 7.1.4. Liraglutide
    • 7.1.5. Dulaglutide
    • 7.1.6. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatric
    • 7.3.2. Adults
  • 7.4. Market Analysis, Insights and Forecast - By Indication
    • 7.4.1. Diabetes
    • 7.4.2. Obesity
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Retail Pharmacies
    • 7.5.3. Online Pharmacies
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.6.1. Germany
    • 7.6.2. U.K.
    • 7.6.3. France
    • 7.6.4. Italy
    • 7.6.5. Spain
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific GLP-1 Receptor Agonists Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Drug
    • 8.1.1. Semaglutide
    • 8.1.2. Exenatide
    • 8.1.3. Lixisenatide
    • 8.1.4. Liraglutide
    • 8.1.5. Dulaglutide
    • 8.1.6. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatric
    • 8.3.2. Adults
  • 8.4. Market Analysis, Insights and Forecast - By Indication
    • 8.4.1. Diabetes
    • 8.4.2. Obesity
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Retail Pharmacies
    • 8.5.3. Online Pharmacies
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America GLP-1 Receptor Agonists Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Drug
    • 9.1.1. Semaglutide
    • 9.1.2. Exenatide
    • 9.1.3. Lixisenatide
    • 9.1.4. Liraglutide
    • 9.1.5. Dulaglutide
    • 9.1.6. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatric
    • 9.3.2. Adults
  • 9.4. Market Analysis, Insights and Forecast - By Indication
    • 9.4.1. Diabetes
    • 9.4.2. Obesity
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital Pharmacies
    • 9.5.2. Retail Pharmacies
    • 9.5.3. Online Pharmacies
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa GLP-1 Receptor Agonists Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Drug
    • 10.1.1. Semaglutide
    • 10.1.2. Exenatide
    • 10.1.3. Lixisenatide
    • 10.1.4. Liraglutide
    • 10.1.5. Dulaglutide
    • 10.1.6. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatric
    • 10.3.2. Adults
  • 10.4. Market Analysis, Insights and Forecast - By Indication
    • 10.4.1. Diabetes
    • 10.4.2. Obesity
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Retail Pharmacies
    • 10.5.3. Online Pharmacies
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Eli Lilly and Company
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Sanofi
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Novo Nordisk A/S
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. AstraZeneca
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Pfizer, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Glenmark Pharmaceuticals Limited
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Teva Pharmaceutical Industries Ltd.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 2: Global GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 3: Global GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Age Group 2019-2032
  • Table 4: Global GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 5: Global GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 6: Global GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Region, 2019-2032
  • Table 7: North America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 8: North America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 9: North America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Age Group 2019-2032
  • Table 10: North America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 11: North America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 12: North America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 13: Europe GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 14: Europe GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 15: Europe GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Age Group 2019-2032
  • Table 16: Europe GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 17: Europe GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 18: Europe GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 19: Asia Pacific GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 20: Asia Pacific GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 21: Asia Pacific GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Age Group 2019-2032
  • Table 22: Asia Pacific GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 23: Asia Pacific GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 24: Asia Pacific GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 25: Latin America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 26: Latin America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 27: Latin America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Age Group 2019-2032
  • Table 28: Latin America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 29: Latin America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 30: Latin America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 31: Middle East & Africa GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Drug, 2019-2032
  • Table 32: Middle East & Africa GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
  • Table 33: Middle East & Africa GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Age Group 2019-2032
  • Table 34: Middle East & Africa GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Indication, 2019-2032
  • Table 35: Middle East & Africa GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
  • Table 36: Middle East & Africa GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global GLP-1 Receptor Agonists Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
  • Figure 2: Global GLP-1 Receptor Agonists Market Value Share (%), by Drug, 2024 & 2032
  • Figure 3: Global GLP-1 Receptor Agonists Market Value Share (%), by Route of Administration, 2024 & 2032
  • Figure 4: Global GLP-1 Receptor Agonists Market Value Share (%), by Age Group, 2024 & 2032
  • Figure 5: Global GLP-1 Receptor Agonists Market Value Share (%), by Indication, 2024 & 2032
  • Figure 6: Global GLP-1 Receptor Agonists Market Value Share (%), by Distribution Channel, 2024 & 2032
  • Figure 7: Global GLP-1 Receptor Agonists Market Value (USD billion), by Region, 2024 & 2032
  • Figure 8: North America GLP-1 Receptor Agonists Market Value (USD billion), by Drug, 2024 & 2032
  • Figure 9: North America GLP-1 Receptor Agonists Market Value Share (%), by Drug, 2024
  • Figure 10: North America GLP-1 Receptor Agonists Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 11: North America GLP-1 Receptor Agonists Market Value Share (%), by Route of Administration, 2024
  • Figure 12: North America GLP-1 Receptor Agonists Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 13: North America GLP-1 Receptor Agonists Market Value Share (%), by Age Group, 2024
  • Figure 14: North America GLP-1 Receptor Agonists Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 15: North America GLP-1 Receptor Agonists Market Value Share (%), by Indication, 2024
  • Figure 16: North America GLP-1 Receptor Agonists Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 17: North America GLP-1 Receptor Agonists Market Value Share (%), by Distribution Channel, 2024
  • Figure 18: North America GLP-1 Receptor Agonists Market Value (USD billion), By Country, 2024 & 2032
  • Figure 19: North America GLP-1 Receptor Agonists Market Value Share (%), By Country, 2024
  • Figure 20: Europe GLP-1 Receptor Agonists Market Value (USD billion), by Drug, 2024 & 2032
  • Figure 21: Europe GLP-1 Receptor Agonists Market Value Share (%), by Drug, 2024
  • Figure 22: Europe GLP-1 Receptor Agonists Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 23: Europe GLP-1 Receptor Agonists Market Value Share (%), by Route of Administration, 2024
  • Figure 24: Europe GLP-1 Receptor Agonists Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 25: Europe GLP-1 Receptor Agonists Market Value Share (%), by Age Group, 2024
  • Figure 26: Europe GLP-1 Receptor Agonists Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 27: Europe GLP-1 Receptor Agonists Market Value Share (%), by Indication, 2024
  • Figure 28: Europe GLP-1 Receptor Agonists Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 29: Europe GLP-1 Receptor Agonists Market Value Share (%), by Distribution Channel, 2024
  • Figure 30: Europe GLP-1 Receptor Agonists Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 31: Europe GLP-1 Receptor Agonists Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 32: Asia Pacific GLP-1 Receptor Agonists Market Value (USD billion), by Drug, 2024 & 2032
  • Figure 33: Asia Pacific GLP-1 Receptor Agonists Market Value Share (%), by Drug, 2024
  • Figure 34: Asia Pacific GLP-1 Receptor Agonists Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 35: Asia Pacific GLP-1 Receptor Agonists Market Value Share (%), by Route of Administration, 2024
  • Figure 36: Asia Pacific GLP-1 Receptor Agonists Market Value (USD billion),by Age Group, 2024 & 2032
  • Figure 37: Asia Pacific GLP-1 Receptor Agonists Market Value Share (%), by Age Group, 2024
  • Figure 38: Asia Pacific GLP-1 Receptor Agonists Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 39: Asia Pacific GLP-1 Receptor Agonists Market Value Share (%), by Indication, 2024
  • Figure 40: Asia Pacific GLP-1 Receptor Agonists Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 41: Asia Pacific GLP-1 Receptor Agonists Market Value Share (%), by Distribution Channel, 2024
  • Figure 42: Asia Pacific GLP-1 Receptor Agonists Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 43: Asia Pacific GLP-1 Receptor Agonists Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 44: Latin America GLP-1 Receptor Agonists Market Value (USD billion), by Drug, 2024 & 2032
  • Figure 45: Latin America GLP-1 Receptor Agonists Market Value Share (%), by Drug, 2024
  • Figure 46: Latin America GLP-1 Receptor Agonists Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 47: Latin America GLP-1 Receptor Agonists Market Value Share (%), by Route of Administration, 2024
  • Figure 48: Latin America GLP-1 Receptor Agonists Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 49: Latin America GLP-1 Receptor Agonists Market Value Share (%), by Age Group, 2024
  • Figure 50: Latin America GLP-1 Receptor Agonists Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 51: Latin America GLP-1 Receptor Agonists Market Value Share (%), by Indication, 2024
  • Figure 52: Latin America GLP-1 Receptor Agonists Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 53: Latin America GLP-1 Receptor Agonists Market Value Share (%), by Distribution Channel, 2024
  • Figure 54: Latin America GLP-1 Receptor Agonists Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 55: Latin America GLP-1 Receptor Agonists Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 56: Middle East & Africa GLP-1 Receptor Agonists Market Value (USD billion), by Drug, 2024 & 2032
  • Figure 57: Middle East & Africa GLP-1 Receptor Agonists Market Value Share (%), by Drug, 2024
  • Figure 58: Middle East & Africa GLP-1 Receptor Agonists Market Value (USD billion), by Route of Administration, 2024 & 2032
  • Figure 59: Middle East & Africa GLP-1 Receptor Agonists Market Value Share (%), by Route of Administration, 2024
  • Figure 60: Middle East & Africa GLP-1 Receptor Agonists Market Value (USD billion), by Age Group, 2024 & 2032
  • Figure 61: Middle East & Africa GLP-1 Receptor Agonists Market Value Share (%), by Age Group, 2024
  • Figure 62: Middle East & Africa GLP-1 Receptor Agonists Market Value (USD billion), by Indication, 2024 & 2032
  • Figure 63: Middle East & Africa GLP-1 Receptor Agonists Market Value Share (%), by Indication, 2024
  • Figure 64: Middle East & Africa GLP-1 Receptor Agonists Market Value (USD billion), by Distribution Channel, 2024 & 2032
  • Figure 65: Middle East & Africa GLP-1 Receptor Agonists Market Value Share (%), by Distribution Channel, 2024
  • Figure 66: Middle East & Africa GLP-1 Receptor Agonists Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 67: Middle East & Africa GLP-1 Receptor Agonists Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 68: Global GLP-1 Receptor Agonists Market Share (%), By Company, 2024